Lutetium (lu177) lilotomab satetraxetan is a Monoclonal Antibody Conjugated owned by Nordic Nanovector, and is involved in 4 clinical trials, of which 3 were completed, and 1 is ongoing.
Betalutin acts against the CD37 B-cell antigen. CD37 is a leukocyte surface antigen which have very similar distribution as CD20 on B cells and B cell lymphomas. It mediates signal transduction events that play a role in the regulation of cell development, activation, growth and motility. and it may play a role in T-cell-B-cell interactions. Thereby, betalutin action on CD37 B-cell antigen stops the growth of tumor cells.
The revenue for Lutetium (lu177) lilotomab satetraxetan is expected to reach a total of $744m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Lutetium (lu177) lilotomab satetraxetan NPV Report.
Lutetium (lu177) lilotomab satetraxetan is originated and owned by Nordic Nanovector.
Lutetium (lu177) lilotomab satetraxetan Overview
Betalutin (177Lu-HH1) is under development for the treatment of non-Hodgkin B-cell lymphoma of subtypes follicular grade I-IIIA, marginal zone, small lymphocytic, lymphoplasmacytic, mantle cell lymphoma and other non-hodkin's lymphomas in combination with CD20. It is administered as an intravenous and parenteral route. The drug candidate is a monoclonal antibody (HH1) conjugated with a radionuclide Lutetium-177 (177Lu). It is a radioimmunotherapeutic developed using nanovector targeting technology. Betalutin targets CD37 antigen.
It was under development for the treatment of diffuse large B-cell lymphoma.
Nordic Nanovector Overview
Nordic Nanovector, formerly Nordic Nanovector is a developer and commercializer of antibody radionuclide conjugates for the treatment of hematological cancers. The company’s lead product candidate includes Betalutin, an antibody radionuclide conjugate developed for the treatment of non-Hodgkin Lymphoma, a life-threatening blood cancer. Its Betalutin consists of tumor-specific antibody HH1, which targets CD37 antigen on the surface of NHL cells. Nordic Nanovector develops products for the treatment of multiple cancer indications by utilizing innovative therapy programs and patented technologies. The company evaluates chimeric anti-CD37 antibodies with different payloads for the treatment of both types of leukemia. It operates in Norway, Switzerland and the UK. Nordic Nanovector is headquartered in Oslo, Norway
The operating loss of the company was NOK442.4 million in FY2021, compared to an operating loss of NOK434.2 million in FY2020. The net loss of the company was NOK441.3 million in FY2021, compared to a net loss of NOK417.1 million in FY2020.
Quick View – Lutetium (lu177) lilotomab satetraxetan
|Highest Development Stage|